The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Future research into MRD-guided treatment of CLL
In this interview, Paula Cramer, MD, University of Cologne, Cologne, Germany, highlights the need for further research on a measurable residual disease (MRD)-guided treatment approach in patients with chronic lymphocytic leukemia (CLL), as time taken to achieve undetectable MRD varies between patients. Dr Cramer outlines plans for a large three-arm Phase III clinical trial, which will compare two fixed-duration regimens (venetoclax plus obinutuzumab and pirtobrutinib plus venetoclax) against an MRD-guided treatment duration of up to 36 months, and Dr Cramer hopes that individualizing treatment duration will result in improved outcomes for patients. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
